Wells Fargo Maintains Overweight on Zymeworks, Raises Price Target to $34

Benzinga Newsdesk www.benzinga.com Positive 80.1%

Neg 0% Neu 0% Pos 80.1%

Wells Fargo analyst Eva Fortea Verdejo maintains Zymeworks (NASDAQ:ZYME) with a Overweight and raises the price target from $33 to $34.